1. Home
  2. BIVI vs PMCB Comparison

BIVI vs PMCB Comparison

Compare BIVI & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.66

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

BUY

Current Price

$0.74

Market Cap

8.3M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
BIVI
PMCB
Founded
2013
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
8.3M
IPO Year
2013
2001

Fundamental Metrics

Financial Performance
Metric
BIVI
PMCB
Price
$1.66
$0.74
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
74.3K
105.2K
Earning Date
05-11-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
277.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.63
52 Week High
$9.09
$1.51

Technical Indicators

Market Signals
Indicator
BIVI
PMCB
Relative Strength Index (RSI) 61.10 50.37
Support Level $1.45 $0.65
Resistance Level $1.69 $0.78
Average True Range (ATR) 0.12 0.05
MACD 0.01 0.00
Stochastic Oscillator 70.73 42.60

Price Performance

Historical Comparison
BIVI
PMCB

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: